Search
Search
Thyroid diseases rank among the most frequent medical conditions, affecting individual patient wellbeing and imposing considerable costs on healthcare systems. Depending on iodine supply, or lack thereof, up to 50% of the total population experience an enlargement of the thyroid gland, also known as goiter. Nodular alterations are found in 5 to 25% of the population, with the frequency increasing in line with age.
Graves' disease is an autoimmune thyroid disease that is characterized by the clinical symptoms of goiter, tachycardia and exophthalmos (abnormal protrusion of the eyeballs). Graves' disease must be distinguished from the functional autonomy of the thyroid since the former can initially be treated by the application of drugs while the latter should be treated by surgery or radioiodine therapy. The measurement of the TSH receptor antibody concentration (TRAK) is key to detecting and adequately treating Graves' disease.
With high sensitivity, specificity, and excellent clinical applicability Thermo Scientific B·R·A·H·M·S TRAK human KRYPTOR Assay is the tool of choice in differential diagnosis and follow-up in Graves’ disease addressing critical clinical questions.
Hashimoto's thyroiditis is another autoimmune disease of the thyroid gland in which the destruction of thyroid tissue ultimately causes hypothyroidism characterized by a multitude of metabolic symptoms. For Hashimoto’s disease, the presence of autoantibodies against thyroid proteins is characteristic, and the most prominent targets are TPO and - to a lesser extent - also thyroglobulin (Tg).
The severity of Hashimoto’s thyroiditis can be assessed with the help of Thermo Scientific B·R·A·H·M·S anti-TPOn and Thermo Scientific B·R·A·H·M·S anti-Tgn Assays. Due to the use of native assay components, both assays achieve improved analytical sensitivity and specificity.
Carcinomas of the thyroid account for 0.5 to 1.54.6% of all prevalent cancerous diseases (1-year prevalence). In 80% of all cases, these are differentiated thyroid carcinomas with a relatively good prognosis, provided the disease is diagnosed at an early stage and carefully followed up.
Differential thyroid carcinoma (DTC) is the most common endocrine cancer worldwide. Initial treatment for this disease consists of total thyroidectomy usually followed by ablation of thyroid remnant with radioiodine. To reliably and effectively monitor patients for recurrent or persistent disease, circulating thyroglobulin (hTg) is used as a biochemical marker. As thyroid cells are the only source of hTg, it is highly specific for DTC and recommended for use as a biomarker by the international clinical practice guidelines.
Our Thermo Scientific B·R·A·H·M·S hTg sensitive KRYPTOR Assay enables laboratories to measure hTg concentrations with excellent sensitivity and accuracy, helping to ensure efficiency and effectiveness.
Thermo Scientific B·R·A·H·M·S KRYPTOR Analyzers are fully automated random-access benchtop immunoanalyzers that use Nobel prize winning TRACE technology to ensure fast and reliable test results for essential indications.
Only KRYPTOR compact PLUS is available for sale in the US.
Our B·R·A·H·M·S hTg sensitive KRYPTOR assay enables laboratories to measure hTg concentrations with excellent sensitivity and accuracy, helping to ensure efficiency and effectiveness.
Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.
© 2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.
KRYPTOR and TRACE are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.